Pharma News

On July 1, 2024, the global pharmaceutical company AbbVie (NYSE: ABBV) officially announced that Mr. Robert A. Michael will take on the role of Chief Executive Officer (CEO) effective immediately and will also join the company's Board of Directors.

Eli Lilly proudly announced that its investigational anti-Aβ antibody Donanemab (brand name Kisunla) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of early symptomatic Alzheimer's disease in adults.

Noteworthy news has arrived - Tang Xiaochun, the head of Merck China's Vaccine Business Unit and Assistant Vice President, has stepped down from his role.

On June 12th, Connect Biopharm filed a notable report with the US Securities and Exchange Commission (SEC) regarding personnel changes.

Sirnaomics, the "leader in China's nucleic acid drug industry" that dazzled the Hong Kong Stock Exchange with its listing in December 2021, has recently found itself embroiled in a wave of high-level management changes.

Sanofi and Regeneron jointly announced that their co-developed drug, dupilumab (Dupixent), has successfully gone through the approval process of the European Medicines Agency (EMA) and been authorized for the treatment of adult patients with COPD.

From a strategic perspective, Bristol-Myers Squibb has been continuously adjusting the priority of its product portfolio in global strategic collaborations, leading to the decision to discontinue MORAb-202.

AstraZeneca stated in a Monday announcement that the European Union's drug regulatory agency has formally accepted the marketing authorization application for its investigational COVID-19 preventive drug sipavibart.

Rocket Pharma announced that the US health regulatory agency had not approved its investigational gene therapy for a rare and severe pediatric disease that significantly impacts the patients' immune system function.

The US Centers for Disease Control and Prevention (CDC) has officially recommended that all individuals aged 6 months and older receive the latest COVID-19 vaccine, regardless of their prior vaccination status, for the 2024-2025 immunization season.

On this past Friday, Federal Judge Michael Shipp carefully evaluated a request from a group of cancer victims to block Johnson & Johnson's bankruptcy plans, and ultimately rejected their motion.

Australia's government formally implemented new e-cigarette regulations this past Monday, aiming to curb the use of e-cigarettes among youth.

Sanofi plans to make a major investment of between €13 billion and €15 billion (equivalent to $14 billion to $16 billion) in its large production facility located in Frankfurt, Germany, for the manufacturing of its insulin brand Lantus.

According to official data released on Saturday, South Korea's export performance in the pharmaceutical and biotechnology sectors showed a significant year-on-year increase in the first half of this year.

President Bola Ahmed Tinubu has officially signed an executive order to implement a zero-tariff, consumption tax, and value-added tax (VAT) incentive policy for imported pharmaceuticals.

On this past Friday, Japanese healthcare product manufacturer Kobayashi Pharmaceutical formally announced that it is conducting a thorough investigation into 76 reported deaths potentially associated with its tablets containing red yeast rice.

On June 26th, three major events in the pharmaceutical industry caused a profound impact both within and outside the sector.

The development history of China's blood product industry can be described as an epic saga of large-scale mergers and acquisitions.

In the global pharmaceutical market, especially in the field of treatment for diabetes and obesity, GLP-1 (glucagon-like peptide-1) drugs are becoming a dominant force thanks to their remarkable efficacy and safety.

In the era of rapid advancement in medical technology, obesity and its related complications are becoming a global public health challenge.